Exploring anti-TB leads from natural products library originated from marine microbes and medicinal plants
Exploring anti-TB leads from natural products library originated from marine microbes and medicinal plants
复制标题
DOI：
10.1007/s10482-012-9777-0
复制
发表时间：
2012-07
期刊：
影响因子：
--
通讯作者：
Xueting Liu;Caixia Chen;Wenni He;Pei Huang;Miaomiao Liu;Qian Wang;Hui Guo;K. Bolla;Yan Lu
中科院分区：
文献类型：
--
作者：
Xueting Liu;Caixia Chen;Wenni He;Pei Huang;Miaomiao Liu;Qian Wang;Hui Guo;K. Bolla;Yan Lu
耐多药结核病（MDR-TB）和结核病与艾滋病病毒（HIV）合并感染已成为全球健康的重大威胁。然而，最后一种被批准用于治疗结核病的真正新药是在40年前发现的。寻找新的有效的抗结核药物从未如此密集。来源于微生物和药用植物的天然产物一直是结核病治疗剂的重要来源。最近的进展已经加快了新型结核病药物的发现速度，包括环境菌株的多样化策略，高通量筛选（HTS）测定和化学多样性。本文将讨论从海洋微生物和植物药物中发现具有抗结核活性的新型天然产物所面临的挑战，包括生物多样性和分类学指导的微生物天然产物库的构建，基于靶点和细胞的HTS，以及生物测定指导的从传统药物中分离抗结核物质。
Multidrug-resistant tuberculosis (MDR-TB) and TB–HIV co-infection have become a great threat to global health. However, the last truly novel drug that was approved for the treatment of TB was discovered 40 years ago. The search for new effective drugs against TB has never been more intensive. Natural products derived from microbes and medicinal plants have been an important source of TB therapeutics. Recent advances have been made to accelerate the discovery rate of novel TB drugs including diversifying strategies for environmental strains, high-throughput screening (HTS) assays, and chemical diversity. This review will discuss the challenges of finding novel natural products with anti-TB activity from marine microbes and plant medicines, including biodiversity- and taxonomy-guided microbial natural products library construction, target- and cell-based HTS, and bioassay-directed isolation of anti-TB substances from traditional medicines.